Key acquisition to spur post-pandemic gains

Baxter’s shares are down about 15% since hitting $92 in April 2020. That’s largely because hospitals postponed elective surgical procedures due to the COVID-19 pandemic. Now that the pandemic is easing, demand for its products is rebounding. The company’s upcoming purchase of hospital equipment maker… Read More

Earnings rise 24.3% at Baxter International

Earnings rise 24.3% at Baxter International

This firm is seeing improved sales and earnings as hospitals and research labs start to order new equipment now that the COVID-19 pandemic is easing. The company will also benefit from its recent acquisitions. 

Meanwhile, the firm continues to make progress on the multi-year restructuring plan… Read More

Baxter International Inc. should rebound post-COVID-19

Baxter International Inc. should rebound post-COVID-19

COVID-19 fears caused people to postpone all but the most urgent doctor visits. 

However, a multi-year restructuring plan should add to cash flow and support this solid dividend even as vaccines increase elective surgeries.

BAXTER INTERNATIONAL INC. (New York symbol BAX; www.baxter.com) makes a variety of medical… Read More